RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47 Sc-conjugated cetuximab

• Published in: BMC cancer Vol. 23; no. 1; p. 652
• Main Authors: Kim, Da-Mi, Lee, So-Young, Lim, Jae-Cheong, Cho, Eun-Ha, Park, Ul-Jae
• Format: Journal Article
• Language: English
• Published: England 12.07.2023
• Subjects: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung - drug therapy; Cetuximab - pharmacology; Cetuximab - therapeutic use; Core Binding Factor Alpha 3 Subunit; ErbB Receptors; Humans; Lung Neoplasms - drug therapy; Pentetic Acid; EGFR-expressing NSCLC; Radioimmunotherapy; Cetuximab; RUNX3; Scandium-47

Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 ( Sc), one of several β -particle-emitting radioisotopes, displays favorable physical and chemical properties for conjugation to monoclonal antibodies. H...